Maralixibat is an ileal bile acid transporter (IBAT) inhibitor approved for the treatment of rare cholestatic liver diseases, including Alagille syndrome, progressive familial intrahepatic cholestasis and biliary atresia. Here, SLC10A2 is linked to Cholestatic liver disease.